Clinical trials: Disease, Chronic
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00542815
- Testing
- MCI-196, Another Phosphate binder (Sevelamer)
- Where
- 115 sites in Austria, Czechia and 13 more
- Volunteers
- 632 people
- Sponsor
- Tanabe Pharma Corporation
Venous Insufficiency
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema (swelling) and subjective symptoms
- Trial name
- NCT00292435
- Testing
- Read vine leaf extract (AS 195)
- Where
- 16 sites in Austria, Czechia and 1 more
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Chronic Ulcer of Leg or Foot, Pressure Injury
A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Safety, and Performance of ConvaFoam™ Dressings in the Management of Indicated Chronic Wound Types.
A prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, safety, and performance of ConvaFoam™ dressings in the management of indicated chronic wound types.
- Trial name
- MORGEN (NCT05632250)
- Testing
- ConvaFoam
- Where
- 5 sites in United States
- Volunteers
- 95 people
- Sponsor
- ConvaTec Inc.
Anemia
Safety and Efficacy of Sustained Erythropoietin Therapy
The purposes of this study are to assess safety, efficacy, and subject satisfaction of EPODURE Biopump (an autologous dermal biopump capable of sustained secretion of therapeutic EPO in the body, using a small tissue explant from…
- Trial name
- NCT00542568
- Testing
- EPODURE (dermal Biopump for erythropoietin)
- Where
- 2 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Medgenics Medical Israel Ltd.
Chronic Kidney Disease (CKD)
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
The study was conducted to assess safety and immunogenicity of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory…
- Trial name
- NCT05422755
- Where
- Indonesia
- Volunteers
- 200 people
- Sponsor
- PT. Daewoong Infion
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT05638776
- Testing
- REGEND001 cell therapy
- Where
- 8 sites in China
- Volunteers
- 58 people
- Sponsor
- Regend Therapeutics
Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00646191
- Testing
- adalimumab
- Volunteers
- 137 people
- Sponsor
- Abbott
Heart Failure
Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients
The primary objective of this study is to assess safety and feasibility of IMPELLA 2.5 in Acute Decompensated Heart Failure patients.
- Trial name
- RELIEF I (NCT01185691)
- Testing
- Impella 2.5
- Volunteers
- 1 people
- Sponsor
- Abiomed Inc.
Degenerative Disc Disease
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in…
- Trial name
- MSB-DR003 (NCT02412735)
- Testing
- Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture
- Where
- 48 sites in United States, Australia
- Volunteers
- 404 people
- Sponsor
- Mesoblast, Ltd.
Cystic Fibrosis, Burkholderia Infection
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
The purpose of the study is to assess the efficacy of Alginate oligosaccharide (OligoG) dry powder for inhalation in cystic fibrosis (CF) patients with a Burkholderia spp. infection.
- Trial name
- SMR-2591 (NCT02453789)
- Testing
- Alginate oligosaccharide
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- AlgiPharma AS
Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease
Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers
This study will assess the safety and efficacy of intramuscular injection of AMG0001 (hepatocyte growth factor [HGF] plasmid) to improve ulcer healing and perfusion in patients with peripheral artery disease.
- Conditions
- Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
- Trial name
- NCT04267640
- Testing
- AMG0001
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- AnGes USA, Inc.
Purpura, Thrombocytopenic, Idiopathic
A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.
- Trial name
- NCT02403440
- Testing
- Hetrombopag Olamine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Progressive Multiple Sclerosis (PMS)
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
- Trial name
- CONSONANCE (NCT03523858)
- Testing
- Ocrelizumab
- Where
- 120 sites in United States, Bosnia and Herzegovina and 22 more
- Volunteers
- 927 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphocytic, Chronic, B-Cell
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
This is a multi-center, Phase II, open label trial evaluating the efficacy and safety of alemtuzumab and fludarabine in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) patients who have received at least one prior…
- Trial name
- ECO-1 (NCT00206726)
- Testing
- Alemtuzumab plus Fludarabine
- Where
- 27 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Pain, Osteoarthritis
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a…
- Conditions
- Pain, Osteoarthritis, Low Back Pain
- Trial name
- NCT00487435
- Testing
- Tapentadol (CG5503) Extended Release (ER)
- Where
- 148 sites in United States, Australia and 2 more
- Volunteers
- 1,166 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hepatitis C, Chronic
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
Phase II: Exploring the efficacy and safety of different doses of SH229 tablets combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing…
- Trial name
- NCT04070235
- Testing
- SH229 tablets, Daclatasvir dihydrochloride
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Heart Failure NYHA Class III, Heart Failure
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure.
- Trial name
- LOWER-PAP (NCT06783335)
- Testing
- Cordella PA Sensor System, Standard of Care Pharmacologic Therapy
- Where
- United States
- Volunteers
- 2,150 people
- Sponsor
- Endotronix, Inc.
Functional Test, COPD, Neuromuscular Disorders, Mechanical Ventilation, Weaning, Disability
MIND Score for Prolonged Mechanical Ventilation
It was decided to develop a comprehensive disability score specifically designed for patients receiving prolonged mechanical ventilation (PMV); the collection of information included in the score should not impose any further…
- Trial name
- MIND (NCT02255058)
- Testing
- No intervention
- Where
- 5 sites in Argentina, Colombia and 1 more
- Volunteers
- 129 people
- Sponsor
- Linde AG
Leukemia
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic…
- Trial name
- NCT00003635
- Testing
- nelarabine
- Where
- 22 sites in United States
- Sponsor
- GlaxoSmithKline
Cerebral Palsy
Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy
Cerebral Palsy (CP) is the first cause of motor disability in children worldwide. ATLAS 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability.
- Trial name
- NCT05926635
- Testing
- ATLAS 2030
- Where
- 5 sites in Spain
- Volunteers
- 60 people
- Sponsor
- MarsiBionics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.